cardiogenesis


Also found in: Medical, Wikipedia.

cardiogenesis

Medical Science, the study of the development of the heart in the embryo.
See also: Heart
Mentioned in ?
References in periodicals archive ?
My preliminary data showed that early CM specific cKO of Dot1L, driven by xMLC2cre, results in lethality at P2, with a phenotype exhibiting increased CM proliferation, demonstrating an essential role for DOT1L in cardiogenesis and CM cell cycle regulation.
NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, today announced that it has successfully completed its acquisition of Cardiogenesis Corporation ("Cardiogenesis").
On September 10, 1996, CardioGenesis filed the original complaint against PLC with the Federal District Court for the Northern District of California.
NEW YORK -- Levi & Korsinsky is investigating the Board of Directors of Cardiogenesis Corporation ("Cardiogenesis" or the "Company") (OTC: CGCP) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to CryoLife, Inc.
9 percent of the outstanding shares of Cardiogenesis Corporation ("Cardiogenesis") (OTCQB: CGCP).
Cardiogenesis Corporation (OTCBB:CGCP:OB), a leading developer of surgical products and accessories used in angina-relieving procedures, today announced the completion of the first robotically-assisted completely endoscopic TMR PLUS procedure.
May 4, 2011 /PRNewswire/ -- Cardiogenesis Corporation (OTCQB: CGCP), a leading developer of surgical products used in the treatment of diffuse coronary artery disease, today reported financial results for its first quarter ended March 31, 2011.
Cardiogenesis Corporation (OTCBB:CGCP:OB), a leading developer of surgical products and accessories used in angina-relieving procedures, issued the following statement today in reaction to a study published in the current issue of The Journal of Thoracic and Cardiovascular Surgery.
CryoLife intends to acquire the remaining outstanding shares of Cardiogenesis through a merger.
Thus far, Cardiogenesis has collaborated with the FDA on a LOA to ensure key scientific and clinical issues regarding the PMC technology and trial are clearly understood and agreed to prior to commencing the study.
With last year's acquisition of worldwide manufacturing and distribution rights to PerClot, and the pending acquisition of Cardiogenesis, we are repositioning the Company for accelerated revenue and earnings growth.
Quinn serves as President and Chief Executive Officer of CardioGenesis, the market leader in surgical products and accessories used in angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Revascularization (PMR) procedures.